Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Dichloroacetate (DCA) has a controversial history, evolving from industrial waste to a potential therapeutic agent.
• Initial research in 2008 indicated anti-cancer effects in animal models, but results have been contradictory.
• DCA is being used off-label in alternative medicine despite a lack of regulatory approval and robust clinical trials.

Purpose of the Study:

• To critically evaluate the existing evidence for dichloroacetate (DCA) as a potential cancer treatment.
• To explore the mechanisms of action and potential therapeutic role of DCA in oncology.
• To determine if current data justifies further clinical investigation into DCA for cancer therapy.

Main Methods:

• Review of existing scientific literature on dichloroacetate (DCA) and its effects on cancer.
• Analysis of in vivo and in vitro studies, including case reports and preclinical data.
• Examination of DCA's known and newly discovered molecular targets, including pyruvate dehydrogenase kinase.

Main Results:

• DCA exhibits controversial anti-cancer properties, with increasing case reports of benefits.
• Evidence suggests DCA can synergize with conventional cancer treatments and other repurposed drugs.
• New molecular targets beyond pyruvate dehydrogenase kinase are being identified for DCA.

Conclusions:

• Despite its controversial past and lack of extensive clinical trials, DCA shows renewed promise in cancer research.
• The potential synergistic effects and novel targets warrant further investigation.
• Well-designed clinical trials are necessary to establish the efficacy and safety of DCA for cancer treatment.